Jeevan Scientific Technology Stocks Witness Spurt in Volume after USFDA Audit
DSIJ Intelligence / 13 Jun 2017
Jeevan Scientific Technology provides a broad range of clinical research services for healthcare/pharmaceutical industries across the globe.
Jeevan Scientific Technology provides a broad range of clinical research services for healthcare/pharmaceutical industries across the globe. On Tuesday, it was locked at 5% upper circuit at Rs 39.80 after successful completion of first audit by the US health regulator. The stock also witnessed a spurt in the volume by more than 2.51 times.
On Monday, the US Food and Drug Administration conducted an un-announced audit of company's corporate and clinical pharmacology centre facilities. The purpose of this audit was to review the BA/BE studies, the company informed.
According to a BSE filing, the auditors were pleased with procedures and processes which resulted with no 483 observation.
The stock has delivered more than 30% returns in a period of one year. It has underperformed BSE small-cap and Nifty Service Sector index over the same period.